Tecovirimat for the Treatment of Mpox - PubMed

3 hours ago

Tecovirimat was evaluated in a phase 3 trial for treating clade II mpox (monkeypox).
The study was a double-blind, randomized, placebo-controlled trial involving 412 participants.
Participants received either tecovirimat or placebo for 14 days, with 344 having confirmed mpox.
Primary outcome was clinical resolution; secondary outcomes included pain reduction and viral DNA clearance.
Results showed no significant difference in clinical resolution between tecovirimat (83%) and placebo (84%).
No substantial differences were observed in pain reduction, lesion healing, or viral clearance.
Adverse events of grade 3 or higher were similar in both groups (4% tecovirimat vs. 3% placebo).
Conclusion: Tecovirimat did not shorten clinical resolution time, reduce pain, or enhance viral clearance in mpox patients.

Hasty Briefsbeta